Australian company (ASX:EMD)has been accepted into the US NIH HEAL Initiative ³Ô¹ÏÍøÕ¾ Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP) program.
NINDS is part of the ³Ô¹ÏÍøÕ¾ Institutes of Health (NIH) and the leading funder of neurological research in the US.
PSPP will evaluate Emyria’s proprietary formulations of Ultra-Pure cannabinoids for suitability as treatments for pain.
Emyria’s managing director Dr Michael Winlo said, “We’re delighted to be accepted into this prestigious program to comprehensively evaluate the suitability of our unique, pharmaceutical-grade formulations to address major unmet needs in pain.
“Our compelling Real World Data has demonstrated that cannabinoids may be useful amongst sufferers of chronic, non-cancer pain and we saw a need to develop reliable, Ultra-Pure dose forms, suitable for registration with major regulators.”
The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is a trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.
Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
The PSPP program, which is part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical models. The PSPP program accepts small molecules, biologics, devices, or natural products for evaluation, from researchers in academia and industry worldwide.
